SG11201701960XA - Compounds and compositions for modulating egfr mutant kinase activities - Google Patents

Compounds and compositions for modulating egfr mutant kinase activities

Info

Publication number: SG11201701960XA
Authority: SG; Singapore
Prior art keywords: compositions; compounds; kinase activities; egfr mutant; mutant kinase
Prior art date: 2014-10-13

Application number

SG11201701960XA

Other languages

English (en)

Inventor

Byung-Chul Suh

Paresh Devidas Salgaonkar

Jaekyoo Lee

Jong Sung Koh

Ho-Juhn Song

In Yong Lee

Jaesang Lee

Dong Sik Jung

Jung-Ho Kim

Se-Won Kim

Original Assignee

Yuhan Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-13

Filing date

2015-10-13

Publication date

2017-04-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201701960X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-13 Application filed by Yuhan Corp filed Critical Yuhan Corp

2017-04-27 Publication of SG11201701960XA publication Critical patent/SG11201701960XA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SG11201701960XA 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities SG11201701960XA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462063394P	2014-10-13	2014-10-13
PCT/KR2015/010784 WO2016060443A2 (en)	2014-10-13	2015-10-13	Compounds and compositions for modulating egfr mutant kinase activities

Publications (1)

Publication Number	Publication Date
SG11201701960XA true SG11201701960XA (en)	2017-04-27

Family

ID=55654993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201701960XA SG11201701960XA (en)	2014-10-13	2015-10-13	Compounds and compositions for modulating egfr mutant kinase activities

Country Status (25)

Country	Link
US (1)	US9593098B2 (es)
EP (3)	EP3604294B1 (es)
JP (3)	JP6524221B2 (es)
KR (4)	KR102662358B1 (es)
CN (2)	CN111686110B (es)
AU (1)	AU2015331166B2 (es)
BR (1)	BR112017007769B1 (es)
CA (1)	CA2962914C (es)
CY (2)	CY1122737T1 (es)
DK (2)	DK3604294T3 (es)
ES (2)	ES2770058T3 (es)
HR (2)	HRP20200201T1 (es)
HU (2)	HUE054848T2 (es)
LT (2)	LT3207035T (es)
MX (3)	MX2020002168A (es)
NZ (1)	NZ730012A (es)
PH (1)	PH12017500488A1 (es)
PL (2)	PL3207035T3 (es)
PT (2)	PT3207035T (es)
RS (2)	RS59900B1 (es)
RU (2)	RU2727700C2 (es)
SG (1)	SG11201701960XA (es)
SI (2)	SI3207035T1 (es)
TW (2)	TWI730331B (es)
WO (1)	WO2016060443A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE054848T2 (hu) *	2014-10-13	2021-09-28	Yuhan Corp	Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
US9938257B2 (en)	2015-09-11	2018-04-10	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
JP2019501222A (ja)	2016-01-07	2019-01-17	シーエスファーマテックリミテッド	Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
MX2018013413A (es) *	2016-05-26	2019-06-06	Zeno Royalties & Milestones Llc	Compuestos inhibidores de egfr.
KR102030886B1 (ko) *	2016-09-23	2019-10-10	재단법인 대구경북첨단의료산업진흥재단	신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AR111469A1 (es) *	2017-04-21	2019-07-17	Yuhan Corp	Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
WO2018228446A1 (zh) *	2017-06-13	2018-12-20	北京浦润奥生物科技有限责任公司	氨基嘧啶类化合物及其制备方法和应用
SI3658547T1 (sl) *	2017-07-28	2023-10-30	Yuhan Corporation	Postopek za pripravo n-(5-(4-(4-formil-3-fenil-1h-pirazol-1-1l)pirimidin-2-ilamino)-4-metoksi -2-morfolinofenil)akrilamida
CN111315742B (zh) *	2017-07-28	2023-09-01	株式会社柳韩洋行	制备氨基嘧啶衍生物的方法
UA125664C2 (uk) *	2017-07-28	2022-05-11	Юхан Корпорейшн	Проміжні сполуки, корисні для синтезу похідних амінопіримідину, спосіб їх отримання й спосіб отримання похідних амінопіримідину з використанням таких сполук
US11267810B2 (en)	2017-08-30	2022-03-08	Shenzhen Targetrx, Inc.	Aminopyrimidine compound and composition comprising same and use thereof
CN108047207A (zh) *	2018-01-30	2018-05-18	天津大学	N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
CN108017633A (zh) *	2018-01-30	2018-05-11	天津大学	N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
KR20200043618A (ko) *	2018-10-18	2020-04-28	주식회사유한양행	아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
WO2020125391A1 (zh) *	2018-12-21	2020-06-25	深圳市塔吉瑞生物医药有限公司	用于抑制蛋白激酶活性的氨基嘧啶类化合物
US11459391B2 (en)	2019-02-26	2022-10-04	Janssen Biotech, Inc.	Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
US20220162203A1 (en) *	2019-03-19	2022-05-26	Voronoi Inc.	Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
CN111747950B (zh) *	2019-03-29	2024-01-23	深圳福沃药业有限公司	用于治疗癌症的嘧啶衍生物
CA3133766A1 (en)	2019-03-29	2020-10-08	Astrazeneca Ab	Osimertinib for use in the treatment of non-small cell lung cancer
WO2020230091A1 (en)	2019-05-14	2020-11-19	Janssen Biotech, Inc.	Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en)	2019-05-14	2023-12-26	Yuhan Corporation	Therapies with 3rd generation EGFR tyrosine kinase inhibitors
CN110128354A (zh) *	2019-06-20	2019-08-16	大连大学	一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法
KR20210032093A (ko)	2019-09-16	2021-03-24	제이투에이치바이오텍 (주)	Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
WO2021094379A1 (en)	2019-11-12	2021-05-20	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN114980883A (zh)	2020-01-20	2022-08-30	阿斯利康(瑞典)有限公司	用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
TW202207940A (zh)	2020-04-14	2022-03-01	美商健生生物科技公司	包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20210369709A1 (en)	2020-05-27	2021-12-02	Astrazeneca Ab	EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (ko) *	2020-06-08	2021-12-15	주식회사 종근당	카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
MX2023002980A (es)	2020-09-14	2023-06-06	Janssen Pharmaceutica Nv	Terapias de combinación de inhibidores del fgfr.
TW202227425A (zh) *	2020-09-18	2022-07-16	南韓商沃若諾伊生物公司	雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
KR20220085735A (ko) *	2020-12-14	2022-06-22	보로노이바이오 주식회사	아이소옥사졸리딘 유도체 화합물 및 이의 용도
EP4335847A1 (en) *	2021-05-07	2024-03-13	Voronoi Inc.	Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
BR112022024068A2 (pt) *	2021-05-17	2023-12-05	Voronoi Inc	Compostos de derivado de heteroarila e usos dos mesmos
EP4349835A1 (en)	2021-06-01	2024-04-10	Hangzhou Solipharma Co., Ltd.	Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof
KR20230054567A (ko)	2021-10-15	2023-04-25	제이투에이치바이오텍 (주)	Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
TW202342057A (zh)	2022-02-07	2023-11-01	美商健生生物科技公司	用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
WO2023187037A1 (en)	2022-03-31	2023-10-05	Astrazeneca Ab	Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209090A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en)	2022-04-28	2024-04-11	Astrazeneca Ab	Heteroaromatic compounds
WO2023209084A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2024002938A1 (en)	2022-06-27	2024-01-04	Astrazeneca Ab	Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024008929A1 (en)	2022-07-08	2024-01-11	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2024096624A1 (en) *	2022-11-03	2024-05-10	Voronoi Inc.	Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030004174A9 (en) *	2000-02-17	2003-01-02	Armistead David M.	Kinase inhibitors
WO2004048343A1 (en) *	2002-11-28	2004-06-10	Schering Aktiengesellschaft	Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
JP4428565B2 (ja)	2004-10-05	2010-03-10	東京エレクトロン株式会社	処理液塗布装置
US20070072894A1 (en)	2005-03-24	2007-03-29	Kempf J V	Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (ja)	2005-07-13	2012-08-22	Ｎｔｎ株式会社	グリース組成物および該グリース封入転がり軸受
JP2009506004A (ja)	2005-08-25	2009-02-12	エフ．ホフマン−ラロシュアーゲー	ｐ３８ＭＡＰキナーゼ阻害剤としての縮合ピラゾール
JP2007117465A (ja)	2005-10-28	2007-05-17	Sharp Corp	集塵器およびそれを備えた電気掃除機
GB2450046B (en)	2006-03-29	2011-03-09	Kt Freetel Co Ltd	Digital device and method for providing additional service by using the same
WO2007117465A2 (en)	2006-03-31	2007-10-18	Abbott Laboratories	Indazole compounds
MX360970B (es) *	2008-06-27	2018-11-23	Avila Therapeutics Inc	Compuestos de heteroarilo y usos de los mismos.
JP5918693B2 (ja) *	2009-05-05	2016-05-18	ダナファーバーキャンサーインスティテュートインコーポレイテッド	Ｅｇｆｒ阻害剤及び疾患の治療方法
JP5740409B2 (ja)	2009-11-13	2015-06-24	ジェノスコ	キナーゼ阻害剤
HUE029988T2 (en) *	2011-02-25	2017-04-28	Yuhan Corp	Diaminopyrimidine derivatives and processes for their preparation
DK3333161T3 (da) *	2011-07-27	2020-05-18	Astrazeneca Ab	2-(2,4,5-substitueret anilin)-pyrimidinderivater som egfr-modulatorer, der er anvendelige til behandling af cancer
ES2668479T3 (es)	2012-01-20	2018-05-18	Genosco	Compuestos de pirimidina sustituidos y su uso como inhibidores de SYK
CN104583195B (zh) *	2012-09-12	2018-08-17	山东亨利医药科技有限责任公司	作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US8957080B2 (en) *	2013-04-09	2015-02-17	Principia Biopharma Inc.	Tyrosine kinase inhibitors
WO2015025197A1 (en) *	2013-08-22	2015-02-26	Jubilant Biosys Limited	Substituted pyrimidine compounds, compositions and medicinal applications thereof
CN111875585B (zh) *	2014-06-12	2023-06-23	上海艾力斯医药科技股份有限公司	一类激酶抑制剂
HUE054848T2 (hu) *	2014-10-13	2021-09-28	Yuhan Corp	Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
CN104788427B (zh) *	2015-02-05	2017-05-31	上海泓博智源医药股份有限公司	3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用

2015
- 2015-10-13 HU HUE19196713A patent/HUE054848T2/hu unknown
- 2015-10-13 WO PCT/KR2015/010784 patent/WO2016060443A2/en active Application Filing
- 2015-10-13 KR KR1020237000623A patent/KR102662358B1/ko active IP Right Grant
- 2015-10-13 EP EP19196713.2A patent/EP3604294B1/en active Active
- 2015-10-13 AU AU2015331166A patent/AU2015331166B2/en active Active
- 2015-10-13 RU RU2017116598A patent/RU2727700C2/ru active
- 2015-10-13 KR KR1020207002949A patent/KR102208775B1/ko active IP Right Grant
- 2015-10-13 PT PT158503144T patent/PT3207035T/pt unknown
- 2015-10-13 CN CN202010422259.0A patent/CN111686110B/zh active Active
- 2015-10-13 ES ES15850314T patent/ES2770058T3/es active Active
- 2015-10-13 HU HUE15850314A patent/HUE048006T2/hu unknown
- 2015-10-13 RU RU2020123547A patent/RU2020123547A/ru unknown
- 2015-10-13 SI SI201531055T patent/SI3207035T1/sl unknown
- 2015-10-13 EP EP21171619.6A patent/EP3929190A1/en active Pending
- 2015-10-13 KR KR1020177012969A patent/KR102073854B1/ko active Protection Beyond IP Right Term
- 2015-10-13 KR KR1020217002019A patent/KR102487451B1/ko active IP Right Grant
- 2015-10-13 DK DK19196713.2T patent/DK3604294T3/da active
- 2015-10-13 LT LTEP15850314.4T patent/LT3207035T/lt unknown
- 2015-10-13 MX MX2020002168A patent/MX2020002168A/es unknown
- 2015-10-13 NZ NZ730012A patent/NZ730012A/en unknown
- 2015-10-13 LT LTEP19196713.2T patent/LT3604294T/lt unknown
- 2015-10-13 RS RS20200101A patent/RS59900B1/sr unknown
- 2015-10-13 RS RS20210608A patent/RS61865B1/sr unknown
- 2015-10-13 TW TW108118264A patent/TWI730331B/zh active
- 2015-10-13 MX MX2017003181A patent/MX2017003181A/es active IP Right Grant
- 2015-10-13 US US14/881,930 patent/US9593098B2/en active Active
- 2015-10-13 CA CA2962914A patent/CA2962914C/en active Active
- 2015-10-13 PT PT191967132T patent/PT3604294T/pt unknown
- 2015-10-13 BR BR112017007769-8A patent/BR112017007769B1/pt active IP Right Grant
- 2015-10-13 ES ES19196713T patent/ES2879474T3/es active Active
- 2015-10-13 DK DK15850314.4T patent/DK3207035T3/da active
- 2015-10-13 PL PL15850314T patent/PL3207035T3/pl unknown
- 2015-10-13 JP JP2017519685A patent/JP6524221B2/ja active Active
- 2015-10-13 EP EP15850314.4A patent/EP3207035B1/en active Active
- 2015-10-13 PL PL19196713T patent/PL3604294T3/pl unknown
- 2015-10-13 CN CN201580055717.9A patent/CN106795144B/zh active Active
- 2015-10-13 TW TW104133539A patent/TWI664173B/zh active
- 2015-10-13 SI SI201531611T patent/SI3604294T1/sl unknown
- 2015-10-13 SG SG11201701960XA patent/SG11201701960XA/en unknown
2017
- 2017-03-10 MX MX2021010761A patent/MX2021010761A/es unknown
- 2017-03-14 PH PH12017500488A patent/PH12017500488A1/en unknown
2019
- 2019-04-26 JP JP2019085608A patent/JP6754864B2/ja active Active
2020
- 2020-02-07 HR HRP20200201TT patent/HRP20200201T1/hr unknown
- 2020-02-17 CY CY20201100143T patent/CY1122737T1/el unknown
- 2020-08-24 JP JP2020141205A patent/JP2020196740A/ja not_active Withdrawn
2021
- 2021-06-14 HR HRP20210949TT patent/HRP20210949T1/hr unknown
- 2021-07-26 CY CY20211100670T patent/CY1124359T1/el unknown

Also Published As

Publication number	Publication date
ES2770058T3 (es)	2020-06-30
HRP20200201T1 (hr)	2020-05-15
CN111686110A (zh)	2020-09-22
CN106795144B (zh)	2020-06-16
BR112017007769A2 (pt)	2018-01-16
TWI730331B (zh)	2021-06-11
PL3207035T3 (pl)	2020-06-01
DK3604294T3 (da)	2021-06-28
KR20230010836A (ko)	2023-01-19
BR112017007769B1 (pt)	2023-10-10
EP3604294B1 (en)	2021-05-05
JP2020196740A (ja)	2020-12-10
US9593098B2 (en)	2017-03-14
DK3207035T3 (da)	2020-01-27
KR102208775B1 (ko)	2021-01-28
RS61865B1 (sr)	2021-06-30
HUE048006T2 (hu)	2020-05-28
EP3929190A1 (en)	2021-12-29
EP3604294A1 (en)	2020-02-05
ES2879474T3 (es)	2021-11-22
PT3604294T (pt)	2021-07-29
CY1124359T1 (el)	2022-07-22
EP3207035A4 (en)	2018-03-14
CN111686110B (zh)	2023-06-16
KR102662358B1 (ko)	2024-04-30
CA2962914A1 (en)	2016-04-21
PT3207035T (pt)	2020-02-19
NZ730012A (en)	2019-06-28
RU2020123547A (ru)	2020-08-18
WO2016060443A2 (en)	2016-04-21
PL3604294T3 (pl)	2021-11-02
KR20210011068A (ko)	2021-01-29
MX2017003181A (es)	2017-07-20
CN106795144A (zh)	2017-05-31
WO2016060443A3 (en)	2016-06-23
HUE054848T2 (hu)	2021-09-28
HRP20210949T1 (hr)	2021-09-03
JP6524221B2 (ja)	2019-06-05
CY1122737T1 (el)	2021-03-12
KR20200014944A (ko)	2020-02-11
RS59900B1 (sr)	2020-03-31
MX2021010761A (es)	2022-06-09
AU2015331166A1 (en)	2017-03-30
SI3604294T1 (sl)	2021-08-31
EP3207035B1 (en)	2019-11-20
MX2020002168A (es)	2021-09-07
PH12017500488A1 (en)	2017-07-31
KR20170066650A (ko)	2017-06-14
JP6754864B2 (ja)	2020-09-16
LT3207035T (lt)	2020-02-25
RU2017116598A3 (es)	2018-11-21
RU2727700C2 (ru)	2020-07-23
CA2962914C (en)	2018-10-23
JP2017530999A (ja)	2017-10-19
AU2015331166B2 (en)	2018-04-26
TW201619150A (zh)	2016-06-01
LT3604294T (lt)	2021-07-26
US20160102076A1 (en)	2016-04-14
TWI664173B (zh)	2019-07-01
TW201938553A (zh)	2019-10-01
KR102487451B1 (ko)	2023-01-11
JP2019163277A (ja)	2019-09-26
KR102073854B1 (ko)	2020-02-05
RU2017116598A (ru)	2018-11-21
SI3207035T1 (sl)	2020-04-30
EP3207035A2 (en)	2017-08-23

Publication	Publication Date	Title
HRP20200201T1 (hr)	2020-05-15	Spojevi i sastavi za moduliranje aktivnosti mutantne egfr kinaze
IL273058A (en)	2020-04-30	Compositions and methods for modulation of PKK expression
HK1258811A1 (zh)	2019-11-22	用於調節cftr 的化合物、組合物和方法
IL286669A (en)	2021-10-31	Compounds and methods for modulating tmprss6 expression
HK1258275A1 (zh)	2019-11-08	用於調節血管緊張素原表達的化合物和方法
IL246879A0 (en)	2016-08-31	Preparations of Epilimod and methods of using them
ZA201700021B (en)	2018-12-19	Alk kinase inhibitor, and preparation method and use thereof
HRP20180920T1 (hr)	2018-07-27	Mješoviti travnjak
EP3102571A4 (en)	2016-12-14	SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS
PL3113774T3 (pl)	2022-06-13	Kompozycje grapiprantu i sposoby ich zastosowania
IL252191B (en)	2022-03-01	Compositions and methods for modulating at2r activity
SG10202003691PA (en)	2020-05-28	Composition for modulating irak1
GB201409661D0 (en)	2014-07-16	Novel compounds and their use as kinase inhibitors
GB201405532D0 (en)	2014-05-14	Novel compounds and their use as Kinase inhibitors